Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02287428 |
|
Recruitment Status :
Recruiting
First Posted : November 10, 2014
Last Update Posted : June 15, 2023
|
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
The Ben & Catherine Ivy Foundation
Accelerate Brain Cancer Cure
Merck Sharp & Dohme LLC
National Institutes of Health (NIH)
Information provided by (Responsible Party):
David Reardon, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 2025 |
| Estimated Study Completion Date : | January 2026 |